The CD200/CD200R expression level and its mechanism of action in hematological malignancy patients

Objective: To explore the CD200/CD200R expression level in the peripheral blood mononuclear cells (PBMC) of hematological malignancy patients and to analyze its mechanism of action. Methods: Thirty hematological malignancy patients who were hospitalized in our hospital from June 2019 to December 2019 were recruited as the study cohort and placed in the disease group, and 30 healthy people were also recruited for the study and placed in the healthy control group. The CD200/CD200R expression level in the two groups' peripheral blood was measured using real-time fluorescent quantitative PCR, and enzyme-linked immunosorbent assays were used to measure the interleukin 17 (IL-17), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) expression levels in the two groups' peripheral blood. We monitored the effects of the effective treatment on the CD200/CD200R level in the hematological malignancy patients. Results: Compared with the healthy group, the CD200 and CD200R mRNA expression level in the PBMC of the disease group was down-regulated, but the IL-17, TNF-alpha and IFN-gamma expression levels in the peripheral blood plasma were up-regulated, and the differences were statistically significant (P < 0.001). The CD200 and CD200R levels showed a negative correlation with the IL-17, TNF-alpha, and IFN-gamma expression levels in the hematological malignancy patients (P < 0.001). The CD200/CD200R expression level was significantly increased in the PBMC of the effectively treated hematological malignancy patients compared with their pre-treatment expression level, and the difference was statistically significant (P < 0.001). Conclusion: CD200/CD200R exhibits a low expression level in hematological malignancy patients, reducing the inhibitory effect on the inflammatory factor expressions, enhancing the inflammatory factors, and mediating the occurrence and development of hematological malignancies.